A provider briefing on Saizen availability in 2026: shortage status, prescribing implications, cost landscape, alternatives, and tools to help patients.
Growth hormone prescribing has never been simple, but the access landscape for Saizen (Somatropin, EMD Serono) has become increasingly complex. Whether you're managing pediatric patients with growth hormone deficiency or adults with childhood-onset or adult-onset GHD, understanding the current state of Saizen availability is essential for continuity of care.
This briefing covers what you need to know about Saizen supply, insurance dynamics, cost considerations, and the tools available to help your patients maintain uninterrupted therapy.
As of early 2026, Saizen is not listed on the FDA's drug shortage database. EMD Serono has not reported formal manufacturing or distribution disruptions.
However, the practical reality for patients is different. Access challenges persist due to:
The broader growth hormone category has not experienced the kind of acute supply disruptions seen with stimulants or GLP-1 agonists, but the structural barriers to access are significant and persistent.
For providers, the key takeaways are:
Before prescribing Saizen, verify your patient's formulary status. An increasing number of plans tier Saizen as non-preferred or exclude it entirely. Prescribing a non-formulary brand can result in:
If your patient's plan does not cover Saizen, consider starting with the plan's preferred somatropin product to avoid therapy gaps. The clinical differences between somatropin brands are minimal — all contain the same 191-amino acid recombinant protein.
Strong documentation is critical for approval. Most plans require:
Having this documentation ready before submitting the prior authorization request can significantly reduce turnaround time.
When transitioning patients between somatropin brands:
Saizen distribution flows through specialty pharmacy networks. Key considerations:
Providers who maintain relationships with 2-3 specialty pharmacies can offer patients more flexibility when the designated plan pharmacy has limited stock.
Saizen pricing remains substantial:
For comparison, Omnitrope (biosimilar) typically costs 20-40% less, and some plans offer $0 copay on their preferred somatropin brand.
Patient assistance resources:
Several tools can streamline the process for both your practice and your patients:
Medfinder helps identify pharmacies with Saizen in stock, reducing the number of calls your staff needs to make. You can direct patients to check availability at medfinder.com/providers as part of your care coordination workflow.
Consider implementing a standardized GH prior authorization checklist in your practice that includes all commonly required documentation elements. This reduces back-and-forth with insurers and speeds approval.
Share these resources with patients who are struggling to access or afford Saizen:
The growth hormone therapy landscape continues to evolve:
Saizen remains a clinically effective somatropin product, but access and affordability challenges require proactive management from prescribers. Staying current on formulary status, maintaining strong prior authorization documentation, and leveraging tools like Medfinder can make a meaningful difference in your patients' ability to access and maintain growth hormone therapy.
For a patient-facing version of this update, share: Saizen shortage update: What patients need to know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
